Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Conway

Pediatric Infectious Diseases Madison, WI Medical Doctor

NPI 1447226188 CMS profile 1030810

2880 University Ave, Madison, WI 53705

Open in the dashboard

General payments

$141,930

109 records reported · program years 2019–2025

Research payments

$3,740

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12,825 paid to institutions, not to them · program year 2019

Through program year 2025, James Conway of Madison, WI is reported in the CMS Open Payments database as having received $141,930 across 109 general payments and $3,740 in research payments paid to them. Separately, studies naming them as principal investigator received $12,825 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,043 19
2024 General $16,389 12
2023 General $36,864 30
2022 General $11,199 7
2021 General $15,435 12
2020 General $6,368 4
2020 Research $3,740 1
2019 General $25,632 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Conway
  • Pediatric Infectious Diseases median
  • Middle half of Pediatric Infectious Diseases
  • National median

In program year 2025, general payments to James Conway were reported at $30,043. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.

Show as a table
Year James Conway Pediatric Infectious Diseases median Middle half National median
2019 $25,632 $175 $34–$2,175 $163
2020 $6,368 $521 $34–$6,009 $114
2021 $15,435 $1,077 $39–$4,557 $132
2022 $11,199 $232 $53–$6,196 $149
2023 $36,864 $140 $52–$4,662 $160
2024 $16,389 $198 $52–$3,860 $164
2025 $30,043 $126 $41–$2,094 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $60,881 47 payments
  2. GlaxoSmithKline, LLC. $33,988 24 payments
  3. Merck Sharp & Dohme Corporation $19,508 18 payments
  4. Moderna TX, Inc. $15,965 10 payments
  5. Pfizer International LLC $7,178 6 payments
  6. Sanofi Pasteur Inc. $4,300 2 payments
  7. Sanofi-Aventis U.S. LLC $73 1 payment
  8. Valneva USA, Inc. $37 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $105,383 40 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,479 9 payments
  3. Travel and Lodging $12,424 39 payments
  4. Honoraria $6,300 3 payments
  5. Food and Beverage $3,272 17 payments
  6. Education $73 1 payment
Products named General payments · program years 2019–2025
  1. PREVNAR 20 Vaccines $17,045 11 payments
  2. PENBRAYA $12,965 13 payments
  3. Moderna Covid-19 Vaccine $7,800 5 payments
  4. BEXSERO $6,084 3 payments
  5. PREVNAR 13 $5,350 3 payments
  6. PREVNAR 20 Vaccines $4,800 3 payments
  7. TRUMENBA $1,800 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi Pasteur Inc. $3,740 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

68

Median for Infectious Disease: 268

Drug cost

$19,532

Median for Infectious Disease: $217,595

Branded share of claims

100%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 56 $17,097
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 12 $2,435

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Records

110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Infectious Diseases in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record